Overactive Bladder Treatment Market Size, Share, Analysis 2032

Report Description

The global overactive bladder treatment market size was USD 2.3 Billion in 2023 and is likely to reach USD 3.3 Billion by 2032, expanding at a CAGR of 4.0% during 2024–2032. The market growth is attributed to the rising ­­advancements in healthcare technologies and the innovation of effective therapeutics.

Overactive bladder (OAB) is a condition characterized by a sudden, intense urge to urinate, often accompanied by symptoms such as nocturia (waking up at night to urinate) and incontinence. Treatment for OAB manages symptoms, improves quality of life, and prevents complications. Regulatory bodies for OAB treatment, including the US Food and Drug Administration (FDA), review and approve medications and devices for OAB treatment, ensuring they meet safety and efficacy standards.

Get Free Sample Report

Rising awareness about early disease diagnosis boosts the demand for effective OAB treatments. OAB treatment involves a multifaceted approach, incorporating various medications and therapies to manage symptoms. Anticholinergics such as oxybutynin, tolterodine, and solifenacin help relax the bladder muscles, reducing urgency and frequency. Beta-3 agonists such as mirabegron stimulate the bladder to store more urine, reducing the need to urinate. Potassium-sparing diuretics such as amiloride help regulate electrolyte levels, which eases OAB symptoms.

Medications such as duloxetine for pain management and gabapentin for neuropathic pain management are used in combination with other treatments. The significance of these medications lies in their ability to alleviate the distressing symptoms of OAB, improving quality of life and reducing the risk of complications. These medications allow patients to regain control over their bladder function by addressing the underlying causes and managing symptoms.

Impact of Artificial Intelligence (AI) on the Overactive Bladder Treatment Market

Artificial intelligence (AI) has the potential to enhance the diagnosis and treatment of overactive bladder (OAB). AI improves the accuracy of bladder cancer diagnosis during cystoscopy by analyzing images and identifying abnormalities. AI algorithms assist in determining the stage of bladder tumors, aiding treatment decisions. Furthermore, AI enhances the accuracy of pathological evaluation, ensuring precise diagnosis.

Overactive Bladder Treatment Market Dynamics

Get Free Sample Report

Major Drivers

Advancements in therapeutics and the rising development of effective drugs are driving the global market. Increasing preference for minimally invasive procedures and neuromodulation techniques contribute to enhanced OAB management. Moreover, the increasing awareness of OAB symptoms and the availability of treatments is expected to propel the global market during the forecast period. Increasing authorization of OAB treatment is fueling the market. For instance,

• In May 2023, Pierre Fabre initiated the EU marketing authorization application process for Vibegron, a treatment for Overactive Bladder (OAB) symptoms, following an agreement with Urovant Sciences GmbH.

Existing Restraints

Rising concerns about the side effects of medication are hindering the global market. Moreover, the high cost of the treatment creates barriers for patients, particularly in regions with limited health insurance coverage, thereby limiting access for certain patient groups.

Emerging Opportunities

Advances in genomics and biomarker research lead to tailored OAB treatments based on individual patient profiles. Furthermore, the increasing investment to improve healthcare infrastructure creates immense opportunities in the market. The rising usage of mobile apps, wearables, and telemedicine enhances patient monitoring and self-management, which is expected to propel the global market during the projected period.

Scope of the Overactive Bladder Treatment Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Regional Analysis

In terms of region, the global overactive bladder treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2023, owing to the high prevalence of OAB in the region. Furthermore, increased healthcare spending, availability of novel treatment options, and favorable reimbursement policies for treatments bolstered the market in the region.

The market in Europe is projected to grow at a significant pace in the coming years, due to the increasing prevalence of OAB. Furthermore, the rising investment in the healthcare sector to improve healthcare infrastructure and develop effective treatment options is expected to boost the regional market during the forecast period.

Get Free Sample Report

Segment Analysis

Therapy Segment Analysis

Based on therapy, the market is divided into anticholinergics, mirabegron, neurostimulation, intravesical instillation, and others. The anticholinergics segment held a large share of the market in 2023. Anticholinergics such as oxybutynin, tolterodine, and solifenacin are the most widely prescribed medications for OAB treatment. These medicines block the action of acetylcholine, a neurotransmitter that stimulates the bladder muscles, thereby reducing the frequency and urgency of urination.

The mirabegron segment is anticipated to expand at a substantial CAGR during the projection period, due to its fewer side effects than others. Mirabegron is a beta-3 agonist that stimulates the bladder to store more urine, reducing the need to urinate. It is marketed under the brand name Myrbetriq and is approved for the treatment of OAB in adults.

Get Free Sample Report

Disease Type Segment Analysis

On the basis of disease type, the global market is bifurcated into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment is anticipated to register a considerable CAGR during the projected period, owing to its high prevalence across the globe. Idiopathic overactive bladder (IOAB) refers to OAB symptoms that occur without any underlying neurological or anatomical abnormalities. This type of OAB is the most common, accounting for approximately 70-80% of all OAB cases.

The neurogenic overactive bladder segment is projected to hold a major share of the market during the assessment years, due to its high severity. Neurogenic overactive bladder (NOAB) requires a more complex treatment approach, involving a multidisciplinary team of healthcare professionals, including urologists, neurologists, and physical therapists. The rising incidence of neurological diseases further propels the segment.

Get Free Sample Report

Distribution Channel Segment Analysis

Based on distribution channel, the overactive bladder treatment market is segmented into retail pharmacies, hospital pharmacies, and others. The retail pharmacy segment registered a robust growth rate in 2023, due to the convenience and easy availability of over-the-counter medications. Moreover, the rising demand for over-the-counter medicines is boosting the segment.

The hospital pharmacies segment is expected to expand at a significant growth rate during the projection period, owing to the increasing demand for specialized treatments. Furthermore, the growing need for hospital-based care is expected to fuel the segment during the projection period.